First Human Dosing of Gerilimzumab
RuiYi initiates clinical trial for autoimmune disorders drug
arGEN-X licensed the worldwide rights to develop and commercialize Gerilimzumab to RuiYi in late 2012. Gerilimzumab was originally generated by arGEN-X using its SIMPLE Antibody™ platform and has been further differentiated with NHance®, its novel, proprietary technology, which prolongs the circulation time and improves tissue distribution of antibodies.
The clinical trial initiated by RuiYi is a double-blind, placebo controlled study in healthy volunteers, with both single and multiple ascending dose protocols. The start of the trial triggers an undisclosed milestone payment by RuiYi to arGEN-X.
Positive results from this study will support advancing Gerilimzumab into trials in patients with autoimmune disorders, including moderate to severe rheumatoid arthritis in 2016.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.